Latest Sales Guidance News

New Hope Corporation lifted quarterly coal production and sales, cut sustaining capital guidance, and issued $300 million in convertible notes to extend debt maturity to 2032.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

Universal Store Holdings has posted a 14% rise in retail sales for the first 43 weeks of FY26, buoyed by strong like-for-like growth across its brands. However, ongoing wholesale challenges at CTC have triggered a $24 million impairment, even as the group maintains its full-year sales and EBITA guidance.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

Paladin Energy has lifted its uranium production guidance for FY2026 at the Langer Heinrich Mine, citing strong ramp-up progress and improved processing metrics. The company also trimmed capital expenditure forecasts while maintaining sales and cost outlooks amid geopolitical uncertainties.

Vmoto Limited forecasts FY26 sales revenue between $73.5 million and $85 million, marking a 57% to 82% increase over FY25, driven by growing orders, strategic partnerships, and regulatory trends favouring electric motorcycles in key markets.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

Elevra Lithium reported solid Q2 FY26 production and revenue results while progressing its North American Lithium brownfield expansion and forging strategic supply partnerships.

MGX Resources reported a $20.8 million half-year loss, driven by a major rockfall at Koolan Island that halted mining and triggered a $60 million asset impairment. The company is pivoting towards gold with its recent acquisition of a 50% stake in the Central Tanami Project.

Elevra Lithium Limited reported record quarterly revenue and gross profit at its North American Lithium operation, even as it navigates short-term production challenges and revises FY2026 guidance downward.